ArticleLasers in surgery and medicine2022
Fractional CO
Article in Lasers in surgery and medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04148651 (Clinical Study of the CO2RE® Laser Device for Treatment of Vulvar Lichen Sclerosus), which is not on this map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study of the CO2RE® Laser Device for Treatment of Vulvar Lichen Sclerosus
Who cites it
8 citing papers in PubMed, 20 citations in OpenAlex.
- Clinical Outcomes of Fractional Carbon Dioxide Laser Treatment in Women With Vulvar Lichen Simplex Chronicus: A Retrospective Study With 12-Month Follow-Up.Lasers in surgery and medicine · 2026Article
- Use of fractional and microablative CO2 laser in cases of vulvar lichen sclerosus: a clinical-histological analysis.Lasers in medical science · 2026Article
- Vulvar Lichen Sclerosus: A Literature Review with Consideration of Integrative Therapies.Integrative medicine (Encinitas, Calif.) · 2025Review
- Multidisciplinary Vulvar Cancer Management: The Dermatologist's Perspective.Life (Basel, Switzerland) · 2024Review
- Efficacy of Fractional COLife (Basel, Switzerland) · 2024Article
- The evidence behind the use of LASER for genitourinary syndrome of menopause, vulvovaginal atrophy, urinary incontinence and lichen sclerosus: A state-of-the-art review.Acta obstetricia et gynecologica Scandinavica · 2022Review
- Extragenital Bullous Lichen Sclerosus Treated with Fractional COClinical, cosmetic and investigational dermatology · 2022Article
- Fractional COLasers in surgery and medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesUncontrolled vulvar lichen sclerosus (VLS) is often associated with distressful symptoms of genital itch, irritation, and pain and can lead to a pathological process including anatomical changes, scarring, and an elevated risk of cancer in the genital area. First-line topical corticosteroid as monotherapy is frequently not adequate to fully suppress disease activity and control symptoms. This study evaluated the efficacy of fractional CO MATERIALS AND
methodsWomen with a diagnosis of VLS supported by histologic findings on biopsy and/or clinical signs on physical examination received up to five monthly laser treatments. Subjects maintained existing topical corticosteroid and any exogenous hormone treatment during the study. Investigators assessed severity (0 = not present, 1 = mild, 2 = moderate, or 3 = severe) of clinical signs and architectural changes present before adjunctive study interventions and at follow-up visits. Subjects reported the presence of clinical symptoms and impact on quality of life on 4- or 5-point Likert scales. The validated Female Sexual Function Index (FSFI) was used to assess changes in sexual function. Four subjects were biopsied before adjunctive laser treatment and at follow-up.
resultsTwelve females, 11 postmenopausal, with a mean age of 57 ± 10 years received three to five monthly CO
conclusionsFractional CO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.